omniture
山东博安生物技术股份有限公司

Latest News

Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million

YANTAI, China, Aug. 27, 2024 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2024 half-y...

2024-08-27 22:55 2580

Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab

A meeting was also held in Germany to announce the results of the international pharmacokinetic sim...

2024-01-12 21:15 2856

Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA

YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18...

2023-12-27 20:50 3169

First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection

YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first ...

2023-10-30 14:51 2189

Boan Biotech's BA1202 Approved for Clinical Trial

-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- ...

2023-05-16 22:02 5791

Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech's Dulaglutide Injection BA5101 in China

YANTAI, China, May 15, 2023 /PRNewswire/ -- Boan Biotech today announced the completion of patient ...

2023-05-15 21:58 4239

First Subject Enrolled in Boan Biotech's International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102

YANTAI, China, May 4, 2023 /PRNewswire/ -- Boan Biotech today announced that an international multi...

2023-05-04 14:40 4051